ArticleJournal of hematology & oncology2018

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Hans Michael Kvasnicka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.